Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.

Published Date: 29 Apr 2023

A parent-based program aims to lessen parental stress while lowering anxiety in adult children.

Read Full News

Todays Updates


CHEST 2026 Preview: Late-Breakers to Watch Out For


CHEST 2026 Preview: Late-Breakers to Watch Out For

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?


Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli


New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio


The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio


New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD


The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH


A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

Todays Updates


CHEST 2026 Preview: Late-Breakers to Watch Out For


CHEST 2026 Preview: Late-Breakers to Watch Out For

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?


Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli


New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio


The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio


New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD


The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH


A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Even when they are not paying attention, children are still learning.

2.

Study finds higher breast cancer rates in areas with more air pollution

3.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

4.

New Zealand and Australian breast cancer rates among the highest in the world, global study finds

5.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot